Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  Review, Journal:  Pipeline Therapies for Gout. (Pubmed Central) -  Dec 22, 2023   
    A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study...Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Journal:  Efficacy of dotinurad in patients with severe renal dysfunction. (Pubmed Central) -  Oct 21, 2023   
    With the 12-month dotinurad treatment, the annual change in the patients' eGFR was significantly improved from -6.0? Dotinurad may have UA-lowering effects and the potential to improve kidney function in patients with severe renal dysfunction.
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Journal:  URAT1 is expressed in cardiomyocytes and dotinurad attenuates the development of diet-induced metabolic heart disease. (Pubmed Central) -  Sep 11, 2023   
    Intriguingly, among various factors related to the pathophysiology of diet-induced obesity, palmitic acid significantly increased URAT1 expression in NRCMs and subsequently induced apoptosis, oxidative stress, and inflammatory responses via MAPK pathway, all of which were reduced by dotinurad. These results indicate that URAT1 is a potential therapeutic target for metabolic heart disease.
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Trial completion date, Trial primary completion date, Head-to-Head:  A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout (clinicaltrials.gov) -  Aug 2, 2023   
    P3,  N=451, Completed, 
    These results indicate that URAT1 is a potential therapeutic target for metabolic heart disease. Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023 | Trial primary completion date: Sep 2023 --> Jun 2023
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion date, Trial primary completion date:  A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants (clinicaltrials.gov) -  Nov 3, 2022   
    P1,  N=26, Recruiting, 
    Recruiting --> Completed Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Enrollment open:  A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants (clinicaltrials.gov) -  Jul 20, 2022   
    P1,  N=26, Recruiting, 
    Therefore, effects of uricosuric agents can be evaluated by the novel method, which is closer to the physiological system compared with previous methods. Not yet recruiting --> Recruiting
  • ||||||||||  Clinical, Journal:  Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs. (Pubmed Central) -  Feb 16, 2022   
    Febuxostat 40 mg and dotinurad 2 mg tended to be more effective than benzbromarone 50 mg, while dotinurad 2 mg and benzbromarone 50 mg tended to be safer than febuxostat 40 mg in hyperuricemic patients with or without gout. Our analysis shows that women and racial and ethnical minorities are underrepresented in controlled clinical trials testing SUA-lowering drugs, with similar pattern across drug classes.
  • ||||||||||  verinurad (RDEA3170) / AstraZeneca, Urece (dotinurad) / Fuji Yakuhin, Mochida
    Review, Journal:  A historical journey of searching for uricosuric drugs. (Pubmed Central) -  Jan 6, 2022   
    Pharmacotherapeutically, a negative urate balance should be the aim of clinicians and then the rational choice of treatment with uricosurics seems quite logical and promising, but has not had a thorough attention of pharma, researchers nor of clinicians, though most gout patients were and still are low excretors. Here, an overview on the 70-year-old journey mankind has made in a search for uricosurics resulting so far in only 1 registered uricosuric per continent.
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Trial completion date, Trial primary completion date:  Study of FYU-981 in Hyperuricemia With or Without Gout (clinicaltrials.gov) -  Dec 6, 2018   
    P3,  N=330, Completed, 
    Dotinurad is expected to be a new therapeutic option in hyperuricemic patients with and without gout. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Oct 2018 | Trial primary completion date: Jan 2020 --> Aug 2018
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Trial completion date, Trial primary completion date, Head-to-Head:  Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout (clinicaltrials.gov) -  Sep 26, 2018   
    P3,  N=201, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Oct 2018 | Trial primary completion date: Jan 2020 --> Aug 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Aug 2018 | Trial primary completion date: Jun 2019 --> Apr 2018
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Trial completion date:  Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) (clinicaltrials.gov) -  Sep 23, 2018   
    P1,  N=24, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types) (clinicaltrials.gov) -  Aug 21, 2018   
    P2,  N=24, Completed, 
    Recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018 Active, not recruiting --> Completed | N=18 --> 24 | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> Aug 2017
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion, Trial completion date, Trial primary completion date:  Mass Balance Study of FYU-981 (clinicaltrials.gov) -  Aug 21, 2018   
    P2,  N=6, Completed, 
    Active, not recruiting --> Completed | N=18 --> 24 | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Jul 2018 | Trial primary completion date: Oct 2017 --> Jan 2017
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion:  Clinical Pharmacology of FYU-981 (Final Formulation) (clinicaltrials.gov) -  Dec 12, 2017   
    P1,  N=12, Completed, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Completed
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    Trial completion:  Drug-drug Interaction Study of FYU-981 and Oxaprozin (clinicaltrials.gov) -  Dec 12, 2017   
    P1,  N=12, Completed, 
    Not yet recruiting --> Completed Not yet recruiting --> Completed
  • ||||||||||  Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
    New P1 trial:  Clinical Pharmacology of FYU-981 (Final Formulation) (clinicaltrials.gov) -  Nov 22, 2017   
    P1,  N=12, Not yet recruiting,